REMS
Contraindicated in:
Use Cautiously in:
EENT: ototoxicity (vestibular and cochlear)
GU: nephrotoxicity
MS: muscle paralysis (high parenteral doses)
Misc: hypersensitivity reactions
Drug-drug:
Renal Impairment
Spectrum:
Absorption: Well absorbed after IM administration. IV administration results in complete bioavailability. Some absorption follows administration by other routes.
Distribution: Widely distributed throughout extracellular fluid; crosses the placenta; small amounts enter breast milk. Poor penetration into CSF.
Half-Life: Neonates <7 days: 3–11.5 hr; Neonates 7–30 days: 3–6 hr; Infants: 3–5 hr; Children: 1–3 hr; Adolescents: 0.5–2.5 hr; Adults: 2–4 hr (↑ in renal impairment).
ROUTE | ONSET | PEAK | DURATION |
IM | rapid | 30–90 min | 8–24 hr |
IV | rapid | 15–30 min‡ | 8–24 hr |
‡All parenterally administered aminoglycosides.
‡Post-distribution peak occurs 30 min after the end of a 30-min infusion and 15 min after the end of a 1-hr infusion.